Gastroenteropancreatic neuroendocrine tumour disease
Not yet recruiting68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide
68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide
- Disease:Gastroenteropancreatic neuroendocrine tumour disease
- Substances:Edotreotide
France- Participants:18–64 years · 65+ years
- Substances:Edotreotide
- Sponsor:Centre De Lutte Contre Le Cancer Eugene Marquis








